Meet Abby

"Abigail 'Abby' is a sweet and happy 2 year old. She adores Ms. Rachel and reading books, especially Brown Bear and "Who Said". She loves Cocomelon, playing with cars and trucks, and many other sensory toys especially ones that play music. Believe it or not, she LOVES *NSYNC. They are quick to calm her down and…

Continue ReadingMeet Abby

Media Requests: How To

Any time is a good time to spread awareness for CTNNB1, but there are some special datesthat you should be familiar with: ● February 28 (or 29) - Rare Disease Day● April 25 - DNA Day● July - Disability Pride Month● July 25 - CTNNB1 Awareness Day● Tuesday after Thanksgiving - Giving Tuesday We suggest reaching…

Continue ReadingMedia Requests: How To

Proclamation Requests: How To

What is a Proclamation? A proclamation is an official document issued by a government official to commemorate a specific time period (ex. day, week, or month) with the goal of honoring and celebrating events or increasing awareness of noteworthy issues among citizens. How to Request a Proclamation Contact the State or Local Government Office - Governors,…

Continue ReadingProclamation Requests: How To

New Research Breakthrough for CTNNB1 Syndrome

A recent study published in Molecular Therapy – Nucleic Acids introduces a promising therapeutic approach for CTNNB1 Syndrome, a rare genetic disorder characterized by severe intellectual disabilities, motor delays, and other neurological impairments. The research focuses on a novel gene therapy technique that aims to restore normal function of the CTNNB1 gene. In this study, researchers utilized advanced…

Continue ReadingNew Research Breakthrough for CTNNB1 Syndrome

CTNNB1 Connect & Cure Attends Rare Advocate Development Workshop in NYC

Last week, our president, Emily Amerson, had the incredible opportunity to attend the Rare Advocate Development (RAD) Workshop in New York City! This impactful event brought together patient advocates, researchers, and industry leaders, all working toward a common goal—driving progress for the rare disease community. The workshop focused on empowering advocates with the tools and knowledge…

Continue ReadingCTNNB1 Connect & Cure Attends Rare Advocate Development Workshop in NYC

Researchers Identify Possible Treatment for Rare Disorder

Researchers at Tufts University School of Medicine and the Graduate School of Biomedical Sciences (GSBS) have identified a small molecule that, in mouse and human cell models, rectifies the underlying molecular cause of a rare genetic developmental disorder linked with motor and intellectual disabilities and some types of autism spectrum disorder. Their most recent research, published in EMBO Molecular Medicine, provides the…

Continue ReadingResearchers Identify Possible Treatment for Rare Disorder

Meet Lily

Lily is 6 years old and is heading into first grade in the fall. School is her absolute favorite place to be, which makes sense because she is a total celebrity in the school! We frequently run into people in town who recognize her and make it a point to tell us how much they adore…

Continue ReadingMeet Lily

Clinical Update! FEVR Publication by Dr. Drew Scoles, Children’s Hospital of Philadelphia

FEVR (Familial Exudative Vitreoretinonpathy) is a major health concern for CTNNB1 patients, and thanks to a recent publication by Dr. Drew Scoles, caregivers now have an important resource for getting the proper testing. In this case series study of 11 CTNNB1 patients, nearly all required ophthalmic care for refractive error and strabismus, and a subset also…

Continue ReadingClinical Update! FEVR Publication by Dr. Drew Scoles, Children’s Hospital of Philadelphia

The first evidence for an efficacious treatment with therapeutic potential for individuals with CTNNB1 syndrome!

We are excited to announce that the research by Dr. Michele Jacob and her team at Tufts University, funded by CTNNB1 Connect & Cure and the NIH, has officially been published by the EMBO Press! Inhibition of GSK3α,β rescues cognitive phenotypes in a preclinical mouse model of CTNNB1 syndrome: https://www.embopress.org/doi/full/10.1038/s44321-024-00110-5 Key Takeaways from the publication:- The…

Continue ReadingThe first evidence for an efficacious treatment with therapeutic potential for individuals with CTNNB1 syndrome!